Ultragenyx Reports the First Patient Dosing of Setrusumab (UX143) in the P-III Program for Osteogenesis Imperfecta
Shots:
- The first patient has been dosed in the P-III portion of the P-II/III study (Orbit) evaluating the effect of setrusumab on annualized clinical fracture rate vs PBO in a ratio (2:1) in ~195 patients aged 5-<26yrs. at 40+ sites across 12 countries. After the completion of P-III primary analysis, all patients will transit to an extension period and receive open-label setrusumab
- The newly initiated P-III study (Cosmic) evaluating setrusumab vs intravenous bisphosphonate (IV-BP) therapy on the annualized total fracture rate in ~65 patients aged 2-<5yrs. at 20+ sites across 8 countries
- The P-II portion of the (Orbit) study results incl. an improvement in biochemical markers & bone density measures reflected the clinical response & induced bone production
Ref: Globe Newswire | Image: Ultragenyx
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
